Cefiderocol for the treatment of bloodstream infection due to MBL-producing Enterobacterales: a single-center retrospective cohort.
Cefiderocol is a potential option for MBL-producing Enterobacterales BSIs, although its efficacy may be limited by the development of treatment-emergent resistance.